Investment
Features
FeesSafety
Academy
More
Pluang+

Compare L3Harris Technologies Inc (LHX) vs Pfizer Inc (PFE) Price & Performance

L3Harris Technologies IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

L3Harris Technologies Inc vs Pfizer Inc — how do they compare? L3Harris Technologies Inc trades at $283.27 (market cap $53.26B), while Pfizer Inc trades at $26.25 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 2.8× L3Harris Technologies Inc's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.

LHXPFE
Market Cap
$53.26B$151.73B
Sector
IndustrialsHealth
52-Week High
$378.48$28.56
52-Week Low
$270.21$23.60
Enterprise Value
$63.71B$203.22B
Dividend Yield
1.75%6.46%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

L3Harris Technologies Inc

LHX trades at $289.72, up 1.06% on the day, with a bearish technical signal but strong fundamental momentum. Recent earnings beats, including Q2 2026 EPS of $3.13 versus $2.80 expected, and a record $42 billion backlog support growth. The company completed a strategic divestiture and secured key defense contracts, enhancing its positioning in missile defense and space systems.

Outlook is positive with analyst consensus price target of $319.33 implying ~10% upside, though technical indicators signal near-term caution. Risks include execution on production ramp-ups and defense budget volatility, but robust cash flow and dividend payments provide shareholder stability.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About L3Harris Technologies Inc

L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.

Read more on LHX

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE